January 23, 2018 / 10:11 PM / 7 months ago

BRIEF-Macrogenics Announces Continuation Of Sophia Study Of Margetuximab Based On Completion Of Interim Futility Analysis

Jan 23 (Reuters) - Macrogenics Inc:

* MACROGENICS ANNOUNCES CONTINUATION OF SOPHIA STUDY OF MARGETUXIMAB BASED ON COMPLETION OF INTERIM FUTILITY ANALYSIS

* MACROGENICS INC - U.S. FDA HAS GRANTED FAST TRACK DESIGNATION FOR INVESTIGATION OF MARGETUXIMAB

* MACROGENICS - GRANTED FAST TRACK DESIGNATION FOR INVESTIGATION OF MARGETUXIMAB FOR TREATMENT OF PATIENTS WITH METASTATIC/ LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER

* MACROGENICS INC - ANNOUNCED COMPLETION OF A PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 SOPHIA TRIAL

* MACROGENICS INC - AN INDEPENDENT DATA SAFETY MONITORING COMMITTEE (DSMC) HAS RECOMMENDED THAT SOPHIA STUDY CONTINUE AS PLANNED WITHOUT MODIFICATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below